open access

Vol 5, No 3 (2020)
Letter to the Editor
Published online: 2020-06-15
Get Citation

Interferon lambda with remdesivir as a potential treatment option in COVID-19

Ishag Adam1, Lukasz Szarpak2, Krzysztof Jerzy Filipiak3, Jacek Smereka4, Marek Dabrowski5, Saeid Ghavami67, Milosz Jaguszewski8
DOI: 10.5603/DEMJ.a2020.0027
·
Disaster Emerg Med J 2020;5(3):174.


Affiliations

  1. Department of Obstetrics and Gynecology, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah, Saudi Arabia
  2. Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
  3. 1st Department of Cardiology, Medical University of Warsaw, Poland
  4. Wroclaw Medical University · Department of Emergency Medical Service, Parkowa Str 34, 50-365 Wroclaw, Poland
  5. Chair and Department of Medical Education, Poznan University of Medical Sciences, Poznan, Poland
  6. Research Institute in Oncology and Hematology, Cancer Care Manitoba, University of Manitoba, Winnipeg, Canada
  7. Cellular and Molecular Research Center, Department of Anatomy, Faculty of Medicine, Iran University of Medical Sciences, Tehran
  8. 1st Department of Cardiology, Medical University of Gdansk, Poland

open access

Vol 5, No 3 (2020)
LETTERS TO THE EDITOR
Published online: 2020-06-15

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

remdesivir, interferon lambda, COVID-19, SARS-CoV-2, treatment

About this article
Title

Interferon lambda with remdesivir as a potential treatment option in COVID-19

Journal

Disaster and Emergency Medicine Journal

Issue

Vol 5, No 3 (2020)

Article type

Letter to the Editor

Pages

174

Published online

2020-06-15

DOI

10.5603/DEMJ.a2020.0027

Bibliographic record

Disaster Emerg Med J 2020;5(3):174.

Keywords

remdesivir
interferon lambda
COVID-19
SARS-CoV-2
treatment

Authors

Ishag Adam
Lukasz Szarpak
Krzysztof Jerzy Filipiak
Jacek Smereka
Marek Dabrowski
Saeid Ghavami
Milosz Jaguszewski

References (5)
  1. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 [Epub ahead of print].
  2. Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020; 40(1): 68–76.
  3. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020; 295(20): 6785–6797.
  4. Hemann EA, Schwerk J, Savan R. IFN-λ 'guts' neutrophil-mediated inflammation. Nat Immunol. 2017; 18(10): 1061–1062.
  5. Mordstein M, Neugebauer E, Ditt V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010; 84(11): 5670–5677.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl